HUNTSVILLE, Ala., Dec. 8 /PRNewswire/ -- SourceCF Clinical Research and Development, a Huntsville, Alabama-based company that focuses on the development of products for people affected by Cystic Fibrosis (CF), announces the licensing through one of its wholly owned subsidiaries of a novel aerosol delivery platform -- the eFlow(R) Electronic Inhaler (PARI GmbH) for specific programs to be announced later.
"While many medications in CF are delivered via inhalation," states Geoff Hunziker, Senior Vice President for the PARI Aerosol Research Institute, USA, "treatment times are often as long as 15 to 20 minutes and can limit patient compliance and the positive benefits that can be associated with these therapies." In-vitro studies conducted with the eFlow(R) have demonstrated up to a four fold reduction in treatment times.
Mike Walters, Managing Director of SourceCF Clinical Research and Development, states, "we are excited with these in-vitro data and the significant reduction in nebulization times seen with the use of the eFlow(R) Electronic Inhaler". Walters added, "We have already initiated several programs around this platform." Based on feedback from FDA, the company is optimistic that it can begin patient trials using this device in early 2004.
About SourceCF Clinical Research and Development: The new company was formed to serve the Cystic Fibrosis community through the development of new treatment options aimed at improving the lives of people living with this disease. "We are excited to serve the Cystic Fibrosis Community in this way" said Michael Walters, President and CEO of SourceCF. "Life expectancy continues to increase through new options and approaches to care delivery and large-scale clinical trials are needed to support this important work," Walters added. For more information, visit http://www.sourcecf.com/
About The PARI Aerosol Research Institute: As a division that falls under the PARI umbrella, the PARI Aerosol Research Institute (ARI) is the research and development arm of the company focused on new aerosol delivery technologies and pharmaceutical formulation of medications including in-vitro aerosol characterization to predict in-vivo drug deposition. The ARI places special emphasis on the interaction between the drug and device with the focus being on the patient.
PARI is a long established company founded in 1906 in Germany that focuses on highly efficient aerosol delivery products for patients with respiratory diseases. For more information, visit http://www.pari.de/
About CF: Cystic fibrosis is a genetic disease affecting approximately 30,000 children and adults in the United States. One in 31 Americans (one in 28 Caucasians) - more than 10 million people - is an unknowing, symptom-less carrier of the defective gene. CF causes the body to produce abnormally thick, sticky mucus, due to the faulty transport of sodium and chloride (salt) within cells lining organs such as the lungs and pancreas, to their outer surfaces. CF has a variety of symptoms. The most common include: very salty- tasting skin; persistent coughing, wheezing or pneumonia; excessive appetite but poor weight gain; and bulky stools. Treatment of CF depends upon the stage of the disease and which organs are involved. For more information, visit http://www.cff.org/